Copyright
©The Author(s) 2015.
World J Hepatol. Jun 28, 2015; 7(12): 1606-1616
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1606
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1606
Table 2 Doses of antivirals in liver transplant candidates and recipients
Peg-IFN-α 2a | 180 μg/wk, subcutaneous | Renal adjustment |
Peg-IFN-α 2b | Weight-based 1.5 μg/kg per week, subcutaneous | No CNI adjustment |
Ribavirin | Weight-based, 1000 mg in patients < 75 kg, 1200 mg in patients ≥ 75 kg, orally twice a day | |
Boceprevir | 800 mg orally three times a day | No renal adjustment |
Telaprevir | 1125 mg orally twice a day | CNI adjustment |
Sofosbuvir | 400 mg daily, orally | |
Daclatasvir | 60 mg daily, orally | No renal adjustment1 |
Simeprevir | 150 mg daily, orally | No CNI adjustment2 |
- Citation: Pipili C, Cholongitas E. Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol 2015; 7(12): 1606-1616
- URL: https://www.wjgnet.com/1948-5182/full/v7/i12/1606.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i12.1606